Kilitch Drugs (India) Limited — Important, 11-02-2025: Financial Result Updates

**Kilitch Drugs (India) Ltd: Financial Summary**

Consolidated financial results for the quarter ended December 31, 2024, show total income of ₹57.89 crore, reflecting a significant increase of 67.00% compared to ₹34.75 crore from last year, driven by higher sales and operational efficiency. Net sales from operations rose to ₹56.17 crore, up from ₹31.79 crore YoY, fueled by increased demand and market expansion.

Net profit stood at ₹5.61 crore, up from ₹1.74 crore year-on-year, resulting in Earnings Per Share (EPS) of ₹3.71, up from ₹1.85. Profitability was influenced by improved operational management and a reduction in certain expense areas, despite slightly higher employee benefit expenses and finance costs.

Operational costs increased by approximately 9.53% compared to the previous quarter due to rising material costs and inflationary pressures. However, effective cost management practices have helped mitigate larger increases and improved margins.

The balance sheet remains robust, with total assets enhancing alongside equity. Cash flow is healthy, indicating the company’s ability to invest in growth strategies while managing its financial obligations.

Kilitch Drugs is poised for growth, focusing on expanding its market presence and enhancing product offerings, indicating a positive outlook in the pharmaceutical sector. Given the strong financial performance and potential for future growth, maintaining a "buy" stance is advisable for investors looking at long-term gains.